story of the week
Adjuvant Sorafenib for RCC at Intermediate or High Risk of Relapse
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
J. Clin. Oncol 2020 Oct 14;[EPub Ahead of Print], T Eisen, E Frangou, B Oza, et alRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.